Note: Several cancers viruses reduce the Vitamin D Receptor activation.
This reduces vitamin D in the blood being available to cells.
- 94+ Vitamin D Receptor pages have CANCER etc. in the title
- VDR and Cancer risk - meta-analysis July 2009
- Vitamin D Receptor Polymorphisms and Cancer (Book Chapter) - 2020
- 59% increased Breast Cancer survival if good VDR - meta-analysis Nov 2020
- See also Colorectal Cancer risk can increase 3X to 30 X (VDR mutations) – Jan 2021
- VitaminDWiki -
37 studies in both categories Virus and Vitamin D Receptor - VitaminDWiki - Vitamin D Receptor activation can be increased in many ways
- There have been
4509 visits to this page
94+ Vitamin D Receptor pages have CANCER etc. in the title
This list is automatically updated
Items found: 97
VDR and Cancer risk - meta-analysis July 2009
__Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk
Sara Raimondi, Harriet Johansson, Patrick Maisonneuve, Sara Gandini
Carcinogenesis, Volume 30, Issue 7, July 2009, Pages 1170–1180, https://doi.org/10.1093/carcin/bgp103It was suggested that vitamin D levels influence cancer development. The vitamin D receptor (VDR) is a crucial mediator for the cellular effects of vitamin D. Results from previous studies on the association of VDR polymorphisms with different cancer types are somewhat contradictory, and the role of VDR in the etiology of cancer is still equivocal. We therefore performed a meta-analysis on the association between the two most studied VDR polymorphisms ( FokI and BsmI ) and any cancer site. Up to January 2009, we identified 67 independent studies. We used random-effects models to provide summary odds ratio (SOR) for VDR polymorphisms and cancer. We tested homogeneity of effects across studies and publication bias and explored between-study heterogeneity. When comparing FokI ff with FF carriers, we found a significant increase in skin cancer [SOR; 95% confidence intervals (CIs): 1.30; 1.04–1.61] and breast cancer (SOR; 95%CI: 1.14; 1.03–1.27) risk. For the same genotype comparison, we found a significantly higher risk of cancer when we pooled estimates from cancer sites possibly associated with vitamin D levels (prostate, breast, skin, ovary, non-Hodgkin lymphoma and colorectal). A significant reduction in prostate cancer risk was observed for carriers of BsmI Bb compared with bb genotype (SOR; 95%CI: 0.83; 0.69–0.99). In Caucasian populations, both Bb and BB carriers had a significant reduced risk of cancer at any site.
In conclusion, this meta-analysis showed that VDR FokI and BsmI polymorphisms might modulate the risk of cancer of breast, skin and prostate and possibly affect cancer risk at any site in Caucasians.
 Download the PDF from VitaminDWiki
Vitamin D Receptor Polymorphisms and Cancer (Book Chapter) - 2020
Sunlight, Vitamin D and Skin Cancer pp 53-114
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1268)
Patrizia GnagnarellaSara RaimondiValentina AristarcoHarriet Ann JohanssonFederica BellerbaFederica CorsoSara GandiniBook: Sunlight, UV, Vitamin D and Receptor, Skin and other Cancers - Dec 2020 entire book is free
Increasing scientific evidence supports the link between vitamin D and cancer risk. The active metabolite 1,25(OH)2D exerts its activity by binding to the vitamin D receptor (VDR), an intracellular receptor that mediates transcriptional activation and repression of target genes. The binding of 1,25(OH)2D to VDR is able to regulate hundreds of different genes. VDR is active in virtually all tissues including the colon, breast, lung, ovary, bone, kidney, parathyroid gland, pancreatic b-cells, monocytes, T lymphocytes, melanocytes, keratinocytes, and also cancer cells.
The relevance of VDR gene restriction fragment length polymorphisms for various types of cancer has been investigated by a great number of studies.
We have carried out a systematic review of the literature to analyze the relevance of more VDR polymorphisms (Fok1, Bsm1, Taq1, Apa1, and Cdx2) for individual malignancies considering ethnicity as a key factor for heterogeneity.
Up to December 2018, we identified 176 independent studies with data to assess the risk of breast, prostate, colorectal, skin (melanoma and non-melanoma skin cancer), lung, ovarian, kidney, bladder, gallbladder, esophageal, thyroid, head and neck, liver and pancreatic cancer, oral squamous cell carcinoma, non-Hodgkin lymphoma, multiple myeloma and sarcoma.
Significant associations with VDR polymorphisms have been reported for prostate (Fok1, Bsm1, Taq1, Apa1, Cdx2), breast (Fok1, Bsm1, Taq1, Apa1, CdX2), colorectal (Fok1, Bsm1, Taq1, Apa1), and skin cancer (Fok1, Bsm1, Taq1). Very few studies reported risk estimates for the other cancer sites.
Conflicting data have been reported for most malignancies, and at present, it is still not possible to make any definitive statements about the importance of the VDR genotype for cancer risk. It seems probable that other factors such as ethnicity, phenotype, 25(OH)D plasma levels, and UV radiation exposure play a role as confounding factors and introduce heterogeneity.
To conclude, there is some indication that VDR polymorphisms may modulate the risk of some cancer sites and in future studies VDR genetic variation should be integrated also with assessment of vitamin D status and stratified by ethnicity.
59% increased Breast Cancer survival if good VDR - meta-analysis Nov 2020
Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
Volume 20, article number 1051, (2020)
Haiyan Xu, Zhenhua Liu, Hongtai Shi & Chunbin WangBackground
A higher vitamin D intake improves the prognosis of early stage breast cancer (BC) patients. We hypothesized that vitamin D intake should refer to vitamin D receptor (VDR) expression. In order to prove this hypothesis, we first intend to evaluate the correlation between VDR expression and prognosis of BC patients using meta-analysis.Methods
Literatures from PubMed, Embase, and the Cochrane Library (last update by May 20, 2020) were retrieved to find studies assessing the prognostic role of VDR in BC. The hazard ratios (HRs) for patients’ survival were extracted for pooled analyses. Subgroup analysis, sensitivity analysis and meta-regression were performed to explore the sources of heterogeneity.Results
Seven articles containing eight studies with 2503 patients were enrolled. The results from the pooled analyses showed that the VDR expression generally had no relationship with BC patients’ overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS), and progression-free survival (PFS) (P > 0.05). Because only the number of studies exploring the relationship between VDR expression and OS is greater than five and there is heterogeneity, we explored the sources of heterogeneity of these studies. Subgroup analyses showed that the VDR expression in the nucleus had no relationship with OS, but high total VDR expression in the nucleus and cytoplasm was related to a better OS (pooled HR = 0.41; 95% CI = 0.18–0.95; P = 0.038). In addition, in subgroup of studies using cut-off values other than ‘immunoreactive score (IRS)>5’ and ‘IRS > 25′, high VDR expression was associated with a better OS (pooled HR = 0.47; 95% CI = 0.30–0.74; P = 0.001). Sensitivity analysis showed that the result pattern was not obviously affected by any single study. Meta-regression showed that the source of heterogeneity was not country (P = 0.657), pathological type (P = 0.614), molecular type (P = 0.423), staining location (P = 0.481), or cut-off value (P = 0.509).Conclusions
The protein expression level of VDR in entire BC cells evaluated by immunohistochemistry is related to the OS of BC patients. It is expected that a more individualized vitamin D intake and a more accurate prognosis assessment can be recommended for BC patients based on the VDR expression. Of course, more preclinical and clinical studies are needed.
 Download the PDF from VitaminDWiki
See also Colorectal Cancer risk can increase 3X to 30 X (VDR mutations) – Jan 2021
VitaminDWiki -
37 studies in both categories Virus and Vitamin D Receptor This list is automatically updated
- Vitamin D preventing and treating COVID - 30,000 publications – Oct 2024
- COVID maximum downregulation of Vitamin D receptor and CYP27B1 resulted in death - Feb 2024
- COVID in hospital stopped by Vitamin D Receptor activators (curcumin, quercetin) – RCT June 2023
- Children with COVID 4X more likely to have poor Vitamin D Receptors (Note: COVID deactivates VDR) – April 2023
- Diabetes 3X more likely if had COVID ICU (VDR was deactivated) - April 2023
- COVID variants protect themselves by deactivating different VDR variants– March 2023
- Dengue Fever decimated by Vitamin D - many studies
- COVID kids were more likely to have a poor VDR (4.3 X), than low Vitamin D (2.6 X) – Sept 2022
- Cancers are associated with low vitamin D, poor vaccination response and perhaps poor VDR – July 2022
- COVID 3X more likely if a poor Receptor (cells get less Vitamin D from the blood) – July 2022
- Long-COVID is now the biggest COVID concern - many studies
- COVID death 12X more likely if poor Vitamin D Receptor (less D gets to cells) - many studies
- COVID severity, ICU, and mortality all associated with poor vitamin D receptor (but not D, everyone had low D) -Dec 2021
- Different Vitamin D Receptor problems cause different COVID problems - Dec 2021
- COVID-19 severity associated with 3 vitamin D genes – Oct 2021
- Poor Vitamin D receptor blocked Vitamin D from fighting avian influenza viruses (in mice) – July 2021
- Epstein-Barr is yet another virus that deactivates the Vitamin D receptor (COVID later suspected as well)– 2010
- COVID-19 symptoms and comorbidities associated with the type of Vitamin D Receptor – Oct 2021
- Enveloped virus infection (RSV, coronavirus, HIV, etc.) 1.5X more likely if poor Vitamin D Receptor – meta-analysis Dec 2018
- COVID-19 outpatients getting Quercetin nanoemulsion had excellent outcomes (Q increased Vitamin D in cells) – RCT – June 2021
- A virus that most adults have (Cytomegalovirus) decreases the amount of Vitamin D which gets to the cells – Jan 2017
- COVID virus alters the activation of 100 vitamin D related genes in the lung – April 2021
- Common sense COVID-19 risk reduction - masks, social distancing, vitamin D - Oct 2020
- AI is examining 170,000 potential COVID-19 treatments, Vitamin D is one of only 6 found – Sept 4, 2020
- Vitamin D Receptor activation should reduce ARDS associated with COVID-19 - June 2020
- Dengue viral production decreased 1000X if activate Vitamin D Receptor (in lab) – July 2020
- Vitamin D, Quercetin, and Estradiol all increase vitamin D in cells and increase genes which reduce COVID-19 – May 21, 2020
- Quercetin and Vitamin D - Allies Against COVID-19
- Risk of enveloped virus infection is increased 50 percent if poor Vitamin D Receptor - meta-analysis Dec 2018
- Hand, foot, and Mouth disease is 14X more likely if poor Vitamin D Receptor – Oct 2019
- Treating herpes reduced incidence of senile dementia by 10 X (HSV1 reduces VDR by 8X) – 2018
- Severe hand, foot, and mouth virus is 2.9 X more likely if poor Vitamin D receptor – Oct 2018
- Hepatitis B virus reduced by 5X the Vitamin D getting to liver cells in the lab – Oct 2018
- Some enveloped virus are 1.2 X more likely if have a poor Vitamin D Receptor -Aug 2018
- Severe Pertussis is 1.5 times more likely if poor vitamin D receptor – Feb 2016
- Dengue Fever associated with poor vitamin D receptor – July 2002
- Dengue virus 2X to 4X more likely if vitamin D receptor gene problems
VitaminDWiki - Vitamin D Receptor activation can be increased in many ways
Resveratrol, Omega-3, Magnesium, Zinc, Quercetin, non-daily Vit D, Curcumin, Berberine, intense exercise, Butyrate Sulforaphane Ginger, Essential oils, etc Note: The founder of VitaminDWiki uses 10 of the 16 known VDR activators
There have been
4509 visits to this page
Vitamin D Receptor (Cancers OR Viruses) - many studies884 visitors, last modified 12 Jun, 2024, This page is in the following categories (# of items in each category)Attached files
ID Name Uploaded Size Downloads 20908 VDR Breast Cancer meta_CompressPdf.pdf admin 02 Mar, 2024 513.60 Kb 46 20904 VDR meta cancer_CompressPdf.pdf admin 02 Mar, 2024 448.71 Kb 19 20903 VDR meta cancer_CompressPdf.pdf admin 02 Mar, 2024 448.71 Kb 14 20902 VDR meta cancer_CompressPdf.pdf admin 02 Mar, 2024 448.71 Kb 20 20900 VDR meta cancer_CompressPdf.pdf admin 02 Mar, 2024 448.71 Kb 47
- VitaminDWiki - Vitamin D Receptor activation can be increased in many ways